Stay updated with breaking news from Celularity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities research analysts expect Celularity Inc. (NASDAQ:CELU – Get Rating) to post earnings of ($0.23) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celularity’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). The company is scheduled to […]
Zacks Investment Research lowered shares of Celularity (NASDAQ:CELU – Get Rating) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports. According to Zacks, “Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified […]
Celularity Inc. (NASDAQ:CELU – Get Rating)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $8.88, but opened at $8.62. Celularity shares last traded at $8.69, with a volume of 234 shares changing hands. A number of research analysts recently commented on CELU shares. Zacks Investment Research downgraded […]
Celularity Inc (NASDAQ:CELU – Get Rating)’s stock price traded down 13.7% during trading on Monday . The company traded as low as $7.60 and last traded at $7.77. 8,943 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 206,427 shares. The stock had previously closed at $9.00. A […]
Celularity Inc (NASDAQ:CELU – Get Rating) was the target of some unusual options trading on Wednesday. Investors purchased 1,734 call options on the stock. This represents an increase of approximately 502% compared to the typical volume of 288 call options. Several hedge funds and other institutional investors have recently modified their holdings of the company. […]